BUSINESS
Generics exempt but Trump’s 100% tariffs a worry for India's innovative pharma, CDMOs
Exporters of innovative medicines and CDMO services face a recalibration — where drugs are made will increasingly matter as much as what they treat
BUSINESS
Emcure slashes price of Poviztra as semaglutide price war in India deepens
The Pune‑based drugmaker said the starting dose of Poviztra will now cost Rs.3,999 a month, a 55 percent cut from earlier levels, while prices across strengths have been lowered by an average of 47 percent.
BUSINESS
Lilly’s first weight loss pill wins US nod, to break access barrier
The approval marks a strategic milestone in the fast‑growing GLP‑1 market, where adoption has been limited by needle aversion, dosing complexity and access barriers.
BUSINESS
Government's push for loose pill sales stirs unease among drugmakers, retailers
While consumer groups see the shift as patient‑friendly, industry participants say the regulatory framework is ill‑equipped to support such a transition
BUSINESS
Novo Nordisk slashes Ozempic, Wegovy prices in India, to fend generic competition
The Danish drugmaker said it will cut the price of the starting dose of Ozempic by 36 percent and that of Wegovy by 48 percent from April 1, making both medicines available at an effective daily cost of Rs 202 for entry‑level therapy.
BUSINESS
Biocon trims workforce as Biologics merger nears completion
The restructuring has impacted employees across R&D, quality, engineering and support functions among others. Sources put the numbers at a few hundred, with cuts spanning multiple levels
BUSINESS
Wockhardt novel antibiotic Zaynich gets thumbs-up from CDSCO expert panel
Such recommendations are typically a precursor to approval by DCGI, though they are not binding.
BUSINESS
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
Tambe, a nearly three‑decade Biocon veteran, will be the first CEO to lead the unified platform after Biocon Biologics was folded into the parent company Biocon.
BUSINESS
Hetero kicks-off generic semaglutide rollout in overseas markets
Initial exports are underway across parts of Africa, Asia and the Middle East, with additional launches planned as regulatory approvals come through.
BUSINESS
Jupiter Hospitals wins 80-year lease for 400-bed hospital in Mumbai's BKC
The company paid Rs 354 crore for the land parcel. On a land‑only basis, the deal implies an upfront cost of roughly Rs 0.9 crore per planned bed — before factoring in build and operating expenses
BUSINESS
As Strides Pharma stabilises balance sheet, focus shifts to growth beyond the US
“We are not looking to enter completely new or unrelated segments..the strategy is to build on our existing capabilities — manufacturing, regulatory, and commercial,” Aditya Kumar said.
BUSINESS
Novo Nordisk betting on clinical depth not discounts to take on low-cost generics, says Vikrant Shrotriya
The patent expiry of semaglutide injections sold by Novo Nordisk as Ozempic and Wegovy has pitted the Danish firm against at least 50 generic brands in India
BUSINESS
Medical device makers warn of crisis, seek quick GST refunds, control on freight charges
AiMeD’s wants the government to come good on its promise to refund excess GST within seven days, a commitment the industry says has not been met
BUSINESS
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
Eris launch coincides with a parallel entry by Natco Pharma, which will also bring its semaglutide injections to market on the first day of patent expiry tomorrow
BUSINESS
Semaglutide’s patent expires today. What does it mean for patients, pharma players and Novo Nordisk?
Novo Nordisk's strategy involves defending its Indian market by combining its premium brand with local distribution strength and lowering prices.
BUSINESS
Hospital chains tap new markets as West Asia conflict slows medical tourism
Inquiries from West Asia have fallen by 25–30% in recent weeks, as uncertainty is forcing patients to delay travel, medical value travel facilitators and hospital executives tell Moneycontrol
BUSINESS
GLP-1 generics surge: Experts warn they are high-risk therapies, not cosmetics
Multinational drugmakers and domestic companies are positioning GLP‑1 drugs as lifestyle enhancers rather than prescription therapies with real risks, they say
BUSINESS
Mankind Pharma buys rights to Rivotril, deepening central nervous system therapy push
Rivotril (clonazepam) is used to treat seizures, anxiety disorders and other neurological conditions
BUSINESS
Zydus, Lupin sign agreement to co‑market weight-loss semaglutide injection in India
Zydus will supply semaglutide, while both companies will sell it under separate brand names
BUSINESS
Sarvodaya Healthcare acquires Niira Radia-founded Nayati Hospital through IBC route
Sarvodaya, through its flagship entity Anshu Hospitals Limited, acquired Nayati for a total resolution consideration of Rs.120 crore.
BUSINESS
Fuel shortage, rising costs threaten production of gloves, syringes and other medical supplies
A spike in polypropylene and polyethylene prices has hit the production of medical-grade polymers, a critical component in more than 86% of all hospital consumables
BUSINESS
Explainer: Why insurance aggregator Policybazaar’s hospital foray is drawing scrutiny
The ambitious hospital venture is incubated by PB Fintech, parent of insurance aggregator Policybazaar. PB Health is building a 1,200‑bed network across Delhi NCR—including a 270‑bed Noida facility and two Gurugram hospitals—while simultaneously expanding into digital preventive care through the acquisition of Fitterfly.
BUSINESS
AM Naik-backed S3V launches indigenous Transcatheter Aortic Valve Replacement system
TAVR, a minimally invasive alternative to open‑heart surgery for severe aortic stenosis, has become the global standard for elderly and high‑risk patients.
BUSINESS
CDSCO warns pharma companies against promotion of weight-loss drugs, tightens oversight
Any advertisement, direct or indirect, that promotes prescription medicines to the general public, inflates efficacy claims or implies guaranteed weight loss outcomes will be deemed misleading and can invite regulatory action, the regulator has said
